Ferring Pharmaceuticals and Evotec AG form strategic research alliance in reproductive medicine and women’s health
- Ferring will access Evotec’s integrated small molecule discovery and development platform to progress new molecules from concept to potential drug candidates.
- Evotec will apply its drug discovery platform to design novel and efficacious treatments.
- Collaboration demonstrates Ferring’s commitment to working with industry leaders such as Evotec to advance reproductive medicine and women’s health.
Saint-Prex, Switzerland & Hamburg, Germany – 17 October, 2018 –
Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions.
Evotec will apply its drug discovery platform to design novel and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development (PDC) and investigational new drug (IND) ready candidates. As part of the alliance, Evotec is eligible for undisclosed research funding and milestones.
“To achieve leadership in reproductive medicine and women’s health, we are expanding beyond our historical expertise in peptides and tackling molecular targets that are best addressed using small molecule therapeutics,” said Per Falk, Chief Science Officer, Ferring Pharmaceuticals. “Evotec is a highly regarded company in this field, and this alliance offers the prospect of significant innovation for patients. Together, we have the potential to make a difference for both men and women who are struggling to start a family, and for women suffering from gynaecological conditions.”
“The integration of our industry-leading small molecule discovery and development platform with Ferring’s expertise in reproductive medicine and women’s health will create a powerful combination that we hope will create a difference for patients suffering from fertility and gynaecological conditions. We very much look forward to working with such an innovative partner,” commented Dr Mario Polywka, Chief Operating Officer of Evotec.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
Forward looking statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
For more information, please contact
Head of Corporate Communications
+41 58 301 09 52 (direct)
+41 79 191 06 32 (mobile)
Senior Manager, Corporate Communications
+41 58 451 40 23 (direct)
+41 79 191 04 86 (mobile)
VP Corporate Communications & Investor Relations
T. +49 (0)40 560 81 255
F. +49 (0)40 560 81 333